Payment overview · 2025
General Payments
$145.50
4 reported records · 3 companies
Healthcare provider profile · identity verified
Andrea Lieber, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BAY CITY, MI · NPI 1659763399
Verified facts
What the public records show
CMS Open Payments records show Andrea Lieber, NP received $145.50 in general payments during 2025 across 4 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 77.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.10 | 77.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.01 | 11.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.39 | 10.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $113.10 | 2 |
| Food and Beverage | $32.40 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $113.10 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 189 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
189 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 618 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 154 |
| Losartan Potassium | Losartan Potassium | 429 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 326 | 110 |
| Metoprolol Tartrate | Metoprolol Tartrate | 303 | 90 |
| Simvastatin | Simvastatin | 291 | 92 |
| Gabapentin | Gabapentin | 290 | 80 |
| Metformin Hcl | Metformin Hcl | 235 | 82 |
| Omeprazole | Omeprazole | 226 | 70 |
| Lisinopril | Lisinopril | 219 | 76 |
| Furosemide | Furosemide | 192 | 78 |
| Mounjaro | Tirzepatide | 189 | 51 |
| Famotidine | Famotidine | 186 | 64 |
| Eliquis | Apixaban | 173 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 55 |
| Potassium Chloride | Potassium Chloride | 152 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 57 |
| Trazodone Hcl | Trazodone Hcl | 152 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 52 |
| Atenolol | Atenolol | 148 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 116 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 32 |
| Allopurinol | Allopurinol | 108 | 35 |
| Carvedilol | Carvedilol | 108 | 36 |
| Ozempic | Semaglutide | 106 | 23 |
| Meloxicam | Meloxicam | 105 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 40 |
| Sertraline Hcl | Sertraline Hcl | 104 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 43 |
| Methylprednisolone | Methylprednisolone | 102 | 88 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 99 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 36 |
| Trulicity | Dulaglutide | 89 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 25 |
| Glimepiride | Glimepiride | 85 | 25 |
| Azithromycin | Azithromycin | 81 | 64 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 18 |
| Montelukast Sodium | Montelukast Sodium | 80 | 31 |
| Spironolactone | Spironolactone | 76 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 28 |
| Donepezil Hcl | Donepezil Hcl | 72 | 21 |
| Alendronate Sodium | Alendronate Sodium | 71 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 24 |
| Metformin Hcl Er | Metformin Hcl | 70 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 23 |
| Ezetimibe | Ezetimibe | 60 | 21 |
| Mirtazapine | Mirtazapine | 60 | 18 |
| Tramadol Hcl | Tramadol Hcl | 60 | 26 |
| Cephalexin | Cephalexin | 59 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 12 |
| Bupropion Xl | Bupropion Hcl | 56 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 50 | 11 |
| Alprazolam | Alprazolam | 49 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 41 |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Warfarin Sodium | Warfarin Sodium | 46 | 15 |
| Finasteride | Finasteride | 45 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 18 |
| Pregabalin | Pregabalin | 42 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 17 |
| Methocarbamol | Methocarbamol | 40 | 22 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Jardiance | Empagliflozin | 37 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 25 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Nystatin | Nystatin | 35 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 26 |
| Ibuprofen | Ibuprofen | 31 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 21 |
| Celecoxib | Celecoxib | 30 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 12 |
| Primidone | Primidone | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 11 |
| Enalapril Maleate | Enalapril Maleate | 28 | 11 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | 11 |
| Prednisone | Prednisone | 24 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 15 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | 11 |
| Lactulose | Lactulose | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 13 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $145.50 · 4 records | Boehringer Ingelheim Pharmaceuticals, Inc. | CAMZYOS, JARDIANCE, MOUNJARO, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error